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Abstract: Liposomal encapsulated cytarabine (DepoCyte®, Mundipharma GmbH, Limburg/
Lahn, Germany) is a slow-release formulation of conventional cytarabine. It is licensed for 
intrathecal use in patients with lymphomatous and leukemic meningitis. DepoCyte® obtained 
superior response rates, improved patient quality of life and improved the time to neurological 
progression in a randomized albeit small clinical trial. In this review we brieﬂ  y summarize the 
clinical data and discuss them in light of clinical problems and possible treatment scenarios.
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Introduction – liposomal encapsulated 
anti-cancer drugs
In an attempt to address some of the problems associated with the lack of tumor selec-
tivity and stability of conventional cytostatic drugs, a variety of novel drug delivery 
systems has been developed. Of these, liposomal drug carrier systems represent a 
mature and versatile technology, and several liposomal formulations of anti-cancer 
drugs have been approved for cancer chemotherapy or are in advanced stages of 
clinical development.
Liposomes are self-assembling colloid structures composed of lipid bilayers 
surrounding aqueous compartments. They were ﬁ  rst described by Bangham et al (1965) 
in the mid 1960s and were initially used as a model system to study biological mem-
branes. The term “liposomes” was introduced in 1968 (Sessa and Weissmann 1968).
Liposomes can be classiﬁ  ed
(i)  according to lamellarity and size (Perez-Soler 1989): Unilamellar vesicles 
comprising one lipid bilayer have diameters of 50 to 250 nm. They contain a 
large aqueous core and are eligible for the encapsulation of water-soluble drugs. 
Multilamellar vesicles composed of several concentric lipid bilayers in an onion-
skin arrangement have diameters of 1 to 5 μm. The high lipid content allows these 
multilamellar vesicles to entrap lipid-soluble drugs passively.
(ii) according to a phylogenetic scheme: Classical or conventional liposomes (ie, 
simple mixtures of phospholipids and cholesterol) target the reticulo-endothelial 
system (RES) and are called “RES-targeted liposomes”. Vesicle size in liposomes 
of similar lipid composition is usually inversely correlated with the amount of RES 
uptake (Senior and Gregoriadis 1982).
Liposomal formulations aim reduce the toxic side effects of conventional cytostatic 
drugs without hampering the efﬁ  cacy. Theoretically, these goals may be reached in 
two ways: (i) the encapsulated drug is prevented from reaching healthy tissue (“site 
avoidance”) and/or (ii) drug concentrations are delivered mainly to neoplastic tissue 
(“drug targeting”).International Journal of Nanomedicine 2008:3(4) 398
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Meanwhile, several liposomal formulations have been 
approved for the treatment of different tumors and have 
become an established addition to the anti-cancer drug 
armamentarium (Hofheinz et al 2005).
In this review we briefly summarize the results of 
liposomal encapsulated cytarabine for the treatment of 
lymphomatous and leukemic meningitis.
The clinical challenge: 
lymphomatous and leukemic 
meningitis
Neoplastic meningitis is characterized by the inﬁ  ltration 
of cancer cells into the leptomeninges and associated with 
a poor prognosis. About 40% to 90% of the patients with 
neoplastic meningitis suffer from neurological symptoms 
(DeAngelis 1998; Chamberlain 2005). More sensitive 
methods such as ﬂ  ow cytometry indicate that central nervous 
system (CNS) involvement in patients with non-Hodgkin’s 
lymphoma (NHL) or leukemia has been underestimated so 
far. A recently reported series using ﬂ  ow cytometry detected 
positive cerebrospinal ﬂ  uid in 73% of patients (Bromberg 
et al 2007). Generally, the treatment of neoplastic menin-
gitis is palliative and the goal is prolongation of survival, 
reduction of neurological symptoms, and improvement of 
qualitiy of life. The treatment of disseminated lympho-
matous meningitis, which may compromise up to 25% of 
high-grade lymphoma patients, requires a long exposure of 
the malignant cells to a high concentration of antineoplastic 
agent to achieve a sufﬁ  ciently cytostatic effect (Bleyer 
1999). As only a few cyctotoxic drugs pass through the 
blood–brain barrier, effective levels cannot be achieved by 
systemic chemotherapy alone (Benesch and Urban 2008). 
Therefore, frequent intrathecal injection of chemothera-
peutic drugs either by lumbar punctures or via ventricular 
access devices has become the mainstay of therapy to 
achieve effective levels of chemotherapeutic agents in the 
cerebrospinal ﬂ  uid (CSF). The antimetabolites methotrex-
ate (MTX) and cytarabine (Ara-C) are agents of choice 
for intrathecal chemotherapy. Given the low proliferation 
index of malignant cells in the CNS, their susceptibility to 
antimetabolite treatment is theoretically increased by longer 
exposure (Bleyer 1999). The removal of MTX or Ara-C from 
the CSF is slow, which gives the rationale for the intrathecal 
use of these drugs.
Until recently, the application of MTX has been preferred 
to Ara-C for its even lower CSF clearance and deeper pen-
etration into the meninges and CNS parenchyma (Bleyer 
1999). Ara-C – a cornerstone in the treatment of hematologic 
malignancies (Johnson 2001) – requires metabolic activation 
by the enzyme cytidine deaminase to exert its cytotoxic 
properties. Within the CSF the activity of cytidine deaminase 
is low and metabolization almost negligible (Zimm et al 
1984). As the terminal half-life of Ara-C in the CSF is 
only 3.4 hours, 2 to 3 intrathecal applications per week are 
required to achieve adequate cytotoxic drug concentration 
over time (Benesch and Urban 2008).
Treatment results with liposomal 
encapsulated cytarabine
Liposomal encapsulated cytarabine (DepoCyte®, 
Mundipharma GmbH, Limburg/Lahn, Germany) is an 
intrathecal injectable suspension of Ara-C encapsulated 
in multivesicular lipid based particles. Multivesicular 
liposomes are structurally distinct from lamellar liposomes. 
They consist of numerous non-concentric water-filled 
polyhedral compartments separated by bilayered liquid septa 
(called DepoFoam®-technology) (Angst and Drover 2006). 
These particles have a diameter of approximately 3 to 30 μm 
consisting of hundreds of aqueous chambers in a honeycomb 
arrangement containing Ara-C. The chambers are separated 
from each other by lipid bilayers consisting of dioleyl-
phosphatidycholine, dipalmitoyl-phosphatidylglycerol, 
cholesterol, and triolein. DepoFoam® particles are therefore 
much larger than conventional uni- or multilamellar 
liposomes bearing a high drug-loading capacity. At storage 
temperatures of 2 to 8 °C the particles are stable for 
12 months. After inthrathecal injection the biodegradation 
of the lipid membranes at body temperature leads to a 
gradual release of Ara-C ensuring prolonged cytotoxic drug 
concentrations of cytarabine in cerebrospinal ﬂ  uid. The lipid 
compounds enter the normal lipid metabolism pathways. 
DepoCyte® has a mean half-life of 130 to 277 hours 
compared with 3 to 4 hours for conventional Ara-C (Zimm 
et al 1984). In a preclinical study even 16 days after injection 
the free-drug concentration was higher than the minimal 
cytotoxic concentration (Kim et al 1987). No Ara-C was 
found in blood plasma after intrathecal administration of 
50 mg of DepoCyte®.
Most of the clinical data published thus far are derived 
from clinical trials or larger case series (Goekbuget et al 2005; 
Björgvinsdóttir et al 2006; Camera et al 2006; Cascavilla et al 
2006; Garcia-Marco et al 2006; Rossi et al 2006; Sancho et al 
2006a, b, 2007; Shapiro et al 2006; Aichberger et al 2007; 
Brion et al 2007). Few reports deal with the prophylactic use 
of DepoCyte® (Anaclerico et al 2006; McClune et al 2007; 
Neumeister et al 2007).International Journal of Nanomedicine 2008:3(4) 399
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For induction therapy a biweekly dosing schedule of 
50 mg DepoCyte® has been established (consolidation and 
maintainance therapy in 4-weekly intervals). Using this 
schedule, cytotoxic CSF levels of Ara-C were found up to 
14 days regardless of the site of drug injection (ventricular 
or lumbar) (Kim et al 1993).
One randomized trial was conducted in patients with 
lymphomatous meningitis. This phase III study compared 
intrathecal liposomal Ara-C with conventional (free) intra-
thecal Ara-C in 28 patients with lymphomatous meningitis 
(Glantz et al 1999b). The experimental treatment arm con-
sisted of biweekly 50 mg DepoCyte® and the reference treat-
ment was Ara-C 50 mg twice weekly for a 1-month induction 
period. In case of response (CSF clearing of lymphoblasts) 
consolidation and maintainance cycles with longer appli-
cation intervals were added. Response rates (ie, clearing 
of CSF and absence of neurological progression) were 
statistically signiﬁ  cant higher in the DepoCyte® arm (71% 
versus 15%; p = 0.006). Moreover, a strong trend in favor 
of DepoCyte® in terms of time to neurological progression 
(78 versus 42 days; p  0.5) and overall survival (99 versus 
63 days; p  0.5) was observed. DepoCyte® treatment was 
associated with an improvement of Karnofsky status at the 
end of the induction treatment (p = 0.041). Consequently, 
the study was stopped before the initially planned sample 
size was achieved. The main side effects of both treatments 
arms were headache and arachnoiditis. Consistent with 
the higher CSF levels of Ara-C in the DepoCyte® group, 
headache (grades 1–3) ocurred in a higher amount of treat-
ment cycles (27% versus 2%). Arachnoiditis (grades 1–3) 
was reported to occur in 22% of DepoCyte® cycles (13% 
with Ara-C). To prevent or mitigate this adverse event, 
concomitant oral dexamethasone treatment (4 mg bid days 
1–5) is recommended.
Another randomized trial compared biweekly DepoCyte® 
50 mg (up to 6 applications) with inthrathecal MTX 
10 mg twice weekly (up to 16 applications) in patients with 
cytologically proven neoplastic meningitis deriving from 
solid tumors (Glantz et al 1999a). A total of 61 patients were 
accrued to receive the drugs either via lumbar puncture or 
an intraventricular Ommaya reservoir. Responses occurred 
in 26% of patients in the DepoCyte® and 20% in the MTX 
group. Median survival was not significantly different 
(105 days with DepoCyte® versus 78 days with MTX), but a 
longer median time to neurological progression was obtained 
with DepoCyte® (58 versus 30 days; p = 0.007). The grades 
and extent of adverse events observed were comparable 
between both groups.
Meanwhile, several phase II studies or larger case series 
with DepoCyte® in patients with lymphomatous or leuke-
mic meningitis have been reported, and similarly to the 
data published by Glantz et al response rates in the range 
of 50% to 70% were noted (for overview see Benesch and 
Urban 2008).
In the prophylactic treatment setting a prospective clini-
cal trial using DepoCyte® as CNS prophylaxis was recently 
published (Jabbour et al 2007). Thirty-three patients with 
previously untreated acute lymphoblastic leukemia or 
lymphoma received liposomal cytarabine concurrently to 
systemic chemotherapy. None of the patients treated with 
DepoCyte® developed isolated CNS relapse. Serious neuro-
toxicity occurred in ﬁ  ve patients within 14 days from the last 
intrathecal therapy (seizure n = 1, encephalitis n = 1, cauda 
equina syndrome n = 2, pseudotumor cerebri n = 1). The 
authors concluded that prior administration of cytotoxic drugs 
passing the blood – brain barrier such as high-dose MTX or 
cytarabine might have increased the risk of neurotoxicity. 
Similar observations have been made by other groups as well, 
eg, in pediatric patients (Benesch et al 2007). Admittedly, it is 
difﬁ  cult to distinguish symptoms by inﬁ  ltration of CNS from 
side effects observed after administration of any substance 
available for intrathecal use alone or in combination with 
systemic chemotherapy (Weiss et al 1974; Resar et al 1991; 
Schiller et al 1992; Benesch and Urban 2008). Nevertheless, 
these observations have led to a discussion among clinicians 
about the safety of DepoCyte® (Chamberlain and Glantz 
2007; Pui 2007).
Concluding remarks
DepoCyte® has consistently shown high response rates in 
the treatment of patients with lymphomatous and leukemic 
meningitis in a randomized clinical trial as well as in several 
case series or phase II studies. Moreover, in this randomized 
trial the superiority over conventional Ara-C with respect 
to the improvement of neurological sympstoms was dem-
onstrated. DepoCyte® is approved in the US and in Europe 
for the intrathecal treatment of lymphomatous meningitis. 
Owing to the scarcity of this disease, it is expected that fur-
ther randomized clinical trials for the treatment of malignant 
leukemic or lymphomatous meningitis will not be conducted 
and that the question of whether DepoCyte® is truly superior 
to conventional cytostatics in the intrathecal treatment will 
remain unresolved. Nonetheless, the mode of administra-
tion favors DepoCyte®. Moreover, cost-utility analysis 
indicates that DepoCyte® is cost-effective (Moeremans 
et al 2004). In view of the recently reported neurological International Journal of Nanomedicine 2008:3(4) 400
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toxicities, the use of DepoCyte® as prophylactic treatment, 
eg, for acute lymphatic leukemia, should remain reserved 
to clinical trials.
Further open questions are the optimal treatment dura-
tion after the initial clearing of CSF from malignant cells, 
the best dosing regimen for consolidation therapy, and the 
interval between the administration of DepoCyte® and other 
potential neurotoxic cytostatic drugs, especially high dose 
methotrexate or Ara-C (Pui 2007). Finally, the potential 
beneﬁ  t of DepoCyte® treatment in malignant meningitis of 
solid tumors remains a challenge to be explored in further 
clinical trials.
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